{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-133525","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.865598+00:00","generated_at":"2026-05-29T07:22:28.804577+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monte Rosa sets RP2D for MRT-2359 at 0.5 mg/day 21/7 schedule; safety, PD data positive","bullets":["RP2D selected: 0.5 mg daily on 21-days-on/7-days-off schedule based on favorable safety and ~60% GSPT1 degradation.","No hypotension, cytokine release syndrome, or clinically significant hypocalcemia observed at any dose.","Doses ≥1.5 mg/day on 5/9 schedule exceeded MTD; thrombocytopenia was DLT; 0.5 and 1 mg were tolerable.","Combination safety assessments started: MRT-2359 + enzalutamide in prostate cancer and + fulvestrant in breast cancer.","Updated biomarker and activity data from Phase 1/2 study expected in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-133525","json":"https://secwatch.observer/filing/0000950170-24-133525.json","markdown":"https://secwatch.observer/filing/0000950170-24-133525.md","text":"https://secwatch.observer/filing/0000950170-24-133525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/0000950170-24-133525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024133525/glue-20241205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:22:28.804577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}